最新临床试验：培布洛珠单抗和Epacadostat治疗复发性、持续性或进展性卵巢透明细胞癌

这是经美国国家癌症研究所批准的一项多中心随机对照二期临床试验，目的是研究pembrolizumab和epacadostat在治疗已复发的卵巢透明细胞癌患者、治疗后仍然存在的患者、生长、扩散或恶化患者方面的作用。用单克隆抗体（如pembrolizumab）进行免疫治疗可能有助于机体免疫系统攻击癌症，并可能干扰肿瘤细胞生长和扩散的能力。epacadostat是免疫抑制关键酶吲哚胺2,3 –双加氧酶1(IDO1)的首个高效、高选择性的口服抑制剂，可能通过阻断细胞生长所需的某些酶来阻止肿瘤细胞的生长。给予培布洛珠单抗和epacadostat治疗卵巢透明细胞癌效果可能会更好。

该临床试验在全美264家医院进行开展。

This phase II trial studies how well pembrolizumab and epacadostat work in treating patients with ovarian clear cell carcinoma that has come back, remains despite treatment, or is growing, spreading, or getting worse. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and epacadostat may work better in treating patients with ovarian clear cell carcinoma.

Trial IDs